Composition for the management of nausea and vomiting
View Patent ↗A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO 3 or. The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).
1. A method for improving the bioavailability of pyridoxal 5-phosphate (PLP) in the plasma in a subject in need of treatment with PLP, said method comprising administering to the subject, as active ingredients, the following ingredients: (i) about 30 mg to about 100 mg of a riboflavin compound selected from (a) riboflavin or a pharmaceutically acceptable salt thereof, (b) riboflavin-5-phosphate or a pharmaceutically acceptable salt thereof, and (c) flavin adenine dinucleotide or a pharmaceutically acceptable salt thereof, (ii) pyridoxine or a pharmaceutically acceptable salt thereof, and optionally (iii) doxylamine or a pharmaceutically acceptable salt thereof, thereby administration of said riboflavin compound improves the bioavailability of PLP in the plasma in said subject, wherein the improved bioavailability of PLP is measurable by the increased PLP in the area under the curve for a period of 0 to 2 hours.
2. The method of claim 1 , wherein the riboflavin compound is riboflavin.
3. The method of claim 1 , wherein the riboflavin compound is riboflavin-5-phosphate.
4. The method of claim 1 , wherein the method comprises administering to the subject about 30 mg to about 50 mg of the riboflavin compound.
5. The method of claim 1 , wherein the subject is administered about 5 mg to about 40 mg of the pyridoxine or the pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the subject is administered about 10 mg to about 30 mg of the pyridoxine or the pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the pyridoxine or the pharmaceutically acceptable salt thereof is pyridoxine hydrochloride.
8. The method of claim 1 , wherein the active ingredients are in the same pharmaceutical composition.
9. The method of claim 8 , wherein the pharmaceutical composition comprises doxylamine or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the doxylamine or the pharmaceutically acceptable salt thereof is doxylamine succinate.
11. The method of claim 10 , wherein the doxylamine or the pharmaceutically acceptable salt thereof is present in an amount of about 5 mg to about 40 mg in said pharmaceutical composition.
12. The method of claim 11 , wherein the doxylamine or the pharmaceutically acceptable salt thereof is present in an amount of about 10 mg to about 30 mg in the pharmaceutical composition.
13. The method of claim 8 , wherein the pharmaceutical composition is an oral dosage form.
14. The method of claim 13 , wherein the oral dosage form is a tablet or a pill.
15. The method of claim 13 , wherein the oral dosage form comprises an immediate release component and a delayed release component.
16. The method of claim 8 , wherein said subject is a pregnant female subject.
17. The method of claim 16 , wherein said pregnant female subject has symptoms of nausea and vomiting of human pregnancy (NVP).
18. The method of claim 8 , wherein the pharmaceutical composition comprises about 10 mg to about 30 mg of pyridoxine hydrochloride and about 30 mg to about 50 mg of riboflavin.
19. The method of claim 18 , wherein the pharmaceutical composition comprises about 10 mg to about 30 mg of doxylamine succinate.